ANN D RHOADS
CIK 1250252 · Chief Financial Officer · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.77M
Companies
10
Total Filings
93
Lifetime Open-Market Net
-$2.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QDEL | Director | 23,257 | $13.99 | $325.4K | $21.2K | 20 | 2026-06-29 |
| GMED | Director | 40,384 | $85.15 | $3.44M | -$3.05M | 22 | 2026-06-08 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 0 | $2.65 | $0 | $80.0K | 7 | 2026-01-28 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | — | $10.15 | — | $0 | 7 | 2025-08-29 |
| Evoke Pharma Inc (EVOK) Delisted | Director | — | $11.00 | — | $0 | 3 | 2021-07-23 |
| Forty Seven, Inc. (FTSV) Delisted | Chief Financial Officer | 0 | — | — | -$183.6K | 3 | 2020-04-07 |
| IRIX | Director | 5,690 | $0.89 | $5.1K | $0 | 3 | 2018-06-15 |
| Evoke Pharma Inc (OMED) Delisted | Director | — | — | — | $0 | 5 | 2018-04-27 |
| ZOGENIX, INC. (ZGNX) Delisted | EVP, CFO, Treasurer & Sec. | 24,901 | $26.68 | $664.4K | $220.8K | 11 | 2016-03-16 |
| NOVELLUS SYSTEMS INC (NVLS) Delisted | Director | 8,750 | — | — | $0 | 5 | 2011-05-13 |
Recent Filings · Page 5 of 10
93 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-16 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-31 | GMED | Grant (A) | — | $0 | EDGAR |
| 2021-07-23 | Evoke Pharma Inc (EVOK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-20 | QDEL | Grant (A) | — | $0 | EDGAR |
| 2021-05-14 | QDEL | Exer (M) | +624 | $0 | EDGAR |
| 2021-05-14 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-03 | GMED | Exer (M) | +15,384 | $164.0K | EDGAR |
| 2021-01-19 | GMED | Grant (A) | — | $0 | EDGAR |
| 2020-10-21 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.